Akeso's Ivonescimab HARMONi-2 Interim Analysis Meets OS Endpoint
nashnova research
Akeso announced its bispecific antibody ivonescimab reached the overall survival (OS) endpoint in a Phase III trial, confirming earlier progression-free survival gains and marking a substantive challenge to Merck's pembrolizumab in first-line lung cancer treatment.
What exactly was this trial testing?
Ivonescimab is the world's first PD-1/VEGF bispecific antibody — a single drug that blocks two tumor-growth pathways at once — developed by Akeso (09926.HK).
The HARMONi-2 trial enrolled 398 patients with advanced non-small cell lung cancer (NSCLC), comparing ivonescimab monotherapy head-to-head against pembrolizumab (Keytruda) monotherapy as first-line treatment.
This means → this is not an early "does it work at all" study. It is a direct face-off against the current global standard of care.
The OS endpoint is reached — how strong is the signal?
An independent data monitoring committee confirmed that the ivonescimab arm achieved a statistically significant and clinically meaningful positive result on the pre-specified OS interim analysis.
The trial had already hit its primary PFS endpoint in May 2024: median PFS of 11.14 months for ivonescimab vs 5.82 months for the control arm, with a hazard ratio of 0.51 (P<0.0001).
In plain terms = an HR of 0.51 means ivonescimab patients faced roughly half the risk of disease progression compared with Keytruda patients. The OS data now confirms this advantage translates into living longer.
What does this mean for the lung cancer treatment landscape?
Ivonescimab was approved in China in 2025 for this indication; commercialization is already underway.
A key breakthrough: ivonescimab overcomes the contraindication of VEGF-targeting drugs in squamous-cell lung cancer patients, offering a chemo-free option.
This means → squamous patients previously had no choice but chemotherapy plus immunotherapy. Ivonescimab monotherapy replaces that combination — less toxicity, better efficacy.
What should investors watch next?
The detailed OS data have not been disclosed yet. Full results will be presented at a future international medical conference and published in a peer-reviewed journal.
This reflects the fact that the current announcement gives only a "positive" conclusion — no median OS or HR figures. The complete dataset is the real trigger for a market re-rating.
In plain terms = we now know the drug "won," but not by how much. The day the full data drop is the defining moment for Akeso's valuation.
市场有风险，内容仅供研究参考，不构成投资建议。